Vertex Pharmaceuticals, Inc. (VRTX)
546.12
-11.84
(-2.12%)
USD |
NASDAQ |
Sep 04, 16:00
545.11
-1.01
(-0.18%)
After-Hours: 20:00
Vertex Pharmaceuticals SG&A Expense (TTM) : 2.008B for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 2.008B |
| March 31, 2026 | 1.850B |
| December 31, 2025 | 1.753B |
| September 30, 2025 | 1.644B |
| June 30, 2025 | 1.570B |
| March 31, 2025 | 1.518B |
| December 31, 2024 | 1.464B |
| September 30, 2024 | 1.456B |
| June 30, 2024 | 1.348B |
| March 31, 2024 | 1.238B |
| December 31, 2023 | 1.137B |
| September 30, 2023 | 1.035B |
| June 30, 2023 | 1.018B |
| March 31, 2023 | 970.60M |
| December 31, 2022 | 944.70M |
| September 30, 2022 | 932.50M |
| June 30, 2022 | 883.89M |
| March 31, 2022 | 863.26M |
| December 31, 2021 | 840.14M |
| September 30, 2021 | 796.78M |
| June 30, 2021 | 783.14M |
| March 31, 2021 | 780.28M |
| December 31, 2020 | 770.46M |
| September 30, 2020 | 753.89M |
| June 30, 2020 | 729.01M |
| Date | Value |
|---|---|
| March 31, 2020 | 693.71M |
| December 31, 2019 | 658.50M |
| September 30, 2019 | 616.43M |
| June 30, 2019 | 594.05M |
| March 31, 2019 | 574.85M |
| December 31, 2018 | 557.62M |
| September 30, 2018 | 539.20M |
| June 30, 2018 | 522.62M |
| March 31, 2018 | 512.56M |
| December 31, 2017 | 496.08M |
| September 30, 2017 | 471.19M |
| June 30, 2017 | 456.54M |
| March 31, 2017 | 440.94M |
| December 31, 2016 | 432.83M |
| September 30, 2016 | 419.98M |
| June 30, 2016 | 413.69M |
| March 31, 2016 | 396.43M |
| December 31, 2015 | 377.08M |
| September 30, 2015 | 358.55M |
| June 30, 2015 | 334.00M |
| March 31, 2015 | 317.06M |
| December 31, 2014 | 305.41M |
| September 30, 2014 | 302.07M |
| June 30, 2014 | 314.60M |
| March 31, 2014 | 343.68M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Gilead Sciences, Inc. | 9.147B |
| Alnylam Pharmaceuticals, Inc. | 1.318B |
| Sionna Therapeutics, Inc. | 37.45M |
| Regeneron Pharmaceuticals, Inc. | 2.743B |
| Biogen, Inc. | 2.594B |